Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.53 |
| ▸ | RXRB | P28702 | 6/20 | 0.53 |
| ▸ | RXRG | P48443 | 5/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312702 | 0.91 | RXRG (0.47) | RXRARXRBRXRGMRGPRX4AVPR2 | |
| SCHEMBL13312693 | 0.90 | RXRA (0.54) | RXRARXRBRXRGMRGPRX4ALDH1A1 | |
| SCHEMBL13312186 | 0.90 | RXRB (0.65) | RXRARXRBRXRGMRGPRX4FFAR1 | |
| SCHEMBL13312696 | 0.90 | RXRA (0.53) | RXRARXRBRXRGMRGPRX4ALDH1A1 | |
| SCHEMBL13312698 | 0.89 | RXRA (0.52) | RXRARXRBRXRGMRGPRX4ALDH1A1 | |
| SCHEMBL13312697 | 0.87 | RXRA (0.51) | RXRARXRBRXRGALDH1A1MAPT | |
| SCHEMBL13312694 | 0.87 | RXRA (0.51) | RXRARXRBRXRGALDH1A1TSHR | |
| SCHEMBL13312639 | 0.87 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4ALDH1A1 | |
| SCHEMBL13312699 | 0.87 | RXRA (0.50) | RXRARXRBRXRGMRGPRX4ALDH1A1 | |
| SCHEMBL13312640 | 0.86 | RXRA (0.54) | RXRARXRBRXRGMRGPRX4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | RXRA 475/4885RXRB 465/4885RXRG 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.